Download RTF

Publications for Chee Khoon Lee
Publications for Chee Khoon Lee
2016
Ramalingam, S., Yang, J., Lee, C., Kurata, T.,
Kim, D., John, T., Nogami, N., Ohe, Y., Janne,
P. (2016). LBA1_PR: Osimertinib as first-line
treatment for EGFR mutation-positive advanced
NSCLC: updated efficacy and safety results from
two Phase I expansion cohorts. Journal of
Thoracic Oncology, 11(4S), S152-S152.
Lindemann, K., Kristensen, G., Mirza, M.,
Davies, L., Hilpert, F., Romero, I., Ayhan, A.,
Burges, A., Rubio, M., Raspagliesi, F., Lee, C.,
Gebski, V., et al (2016). Poor concordance
between CA-125 and RECIST at the time of
disease progression in patients with
platinum-resistant ovarian cancer: analysis of the
AURELIA trial. Annals of Oncology, 27(8),
1505-1510. <a
href="http://dx.doi.org/10.1093/annonc/mdw238
">[More Information]</a>
Trillsch, F., Mahner, S., Hilpert, F., Davies, L.,
Garcia-Martinez, E., Kristensen, G., Savarese,
A., Vuylsteke, P., Los, M., Zagouri, F., Gebski,
V., Lee, C., et al (2016). Prognostic and
predictive effects of primary versus secondary
platinum resistance for bevacizumab treatment
for platinum-resistant ovarian cancer in the
AURELIA trial. Annals of Oncology, 27(9),
1733-1739. <a
href="http://dx.doi.org/10.1093/annonc/mdw236
">[More Information]</a>
Lee, C., Davies, L., Gebski, V., Lord, S., Di Leo,
A., Johnston, S., Geyer, C., Cameron, D., Press,
M., Ellis, C., Marschner, I., Simes, R., et al
(2016). Serum human epidermal growth factor 2
extracellular domain as a predictive biomarker
for lapatinib treatment efficacy in patients with
advanced breast cancer. Journal of Clinical
Oncology, 34(9), 936-944. <a
href="http://dx.doi.org/10.1200/JCO.2015.62.47
67">[More Information]</a>
Vickers, M., Lee, C., Tu, D., Wheatley-Price, P.,
Parulekar, W., Brundage, M., Moore, M., Au, H.,
O'Callaghan, C., Jonker, D., et al (2016).
Significance of baseline and change in quality of
life scores in predicting clinical outcomes in an
international phase III trial of advanced
pancreatic cancer: NCIC CTG PA.3.
Pancreatology, 16(6), 1106-1112. <a
href="http://dx.doi.org/10.1016/j.pan.2016.08.01
3">[More Information]</a>
2015
Price, T., Bruhn, M., Lee, C., Hardingham, J.,
Townsend, A., Robledo, K., Simes, R.,
Weickhardt, A., Wrin, J., Wilson, K., Gebski, V.,
et al (2015). Correlation of extended RAS and
PIK3CA gene mutation status with outcomes
from the phase III AGITG MAX STUDY
involving capecitabine alone or in combination
with bevacizumab plus or minus mitomycin C in
advanced colorectal cancer. British Journal of
Cancer, 112(6), 963-970. <a
href="http://dx.doi.org/10.1038/bjc.2015.37">[M
ore Information]</a>
Lee, C., Goldstein, D., Gibbs, E., Joensuu, H.,
Zalcberg, J., Verweij, J., Casali, P., Maki, R.,
Cioffi, A., Lord, S., et al (2015). Development
and validation of prognostic nomograms for
metastatic gastrointestinal stromal tumour treated
with imatinib. European Journal of Cancer,
51(7), 852-860. <a
href="http://dx.doi.org/10.1016/j.ejca.2015.02.01
5">[More Information]</a>
Lee, C., Lord, S., Grunewald, T., Gebski, V.,
Hardy-Bessard, A., Sehouli, J., Woie, K.,
Heywood, M., Schauer, C., Vergote, I., et al
(2015). Impact of secondary cytoreductive
surgery on survival in patients with platinum
sensitive recurrent ovarian cancer: Analysis of
the CALYPSO trial. Gynecologic Oncology,
136(1), 18-24. <a
href="http://dx.doi.org/10.1016/j.ygyno.2014.09.
017">[More Information]</a>
Lee, C., Wu, Y., Ding, P., Lord, S., Inoue, A.,
Zhou, C., Mitsudomi, T., Rosell, R., Pavlakis,
N., Links, M., Gebski, V., et al (2015). Impact of
Specific Epidermal Growth Factor Receptor
(EGFR) Mutations and Clinical Characteristics
on Outcomes After Treatment With EGFR
Tyrosine Kinase Inhibitors Versus
Chemotherapy in EGFR-Mutant Lung Cancer: A
Meta-Analysis. Journal of Clinical Oncology,
33(17), 1958-1965. <a
href="http://dx.doi.org/10.1200/JCO.2014.58.17
36">[More Information]</a>
Weickhardt, A., Williams, D., Lee, C., Chionh,
F., Simes, R., Murone, C., Byth Wilson, K.,
Parry, M., Asadi, K., Scott, A., et al (2015).
Vascular endothelial growth factor D expression
is a potential biomarker of bevacizumab benefit
in colorectal cancer. British Journal of Cancer,
113(1), 37-45. <a
href="http://dx.doi.org/10.1038/bjc.2015.209">[
More Information]</a>
2014
Hocking, C., Hardingham, J., Broadbridge, V.,
Wrin, J., Townsend, A., Tebbutt, N., Cooper, J.,
Ruszkiewicz, A., Lee, C., Price, T. (2014). Can
we accurately report PTEN status in advanced
colorectal cancer? BMC Cancer, 14(1), 1-7. <a
href="http://dx.doi.org/10.1186/1471-2407-14-1
28">[More Information]</a>
Tjokrowidjaja, A., Lee, C., Houssami, N., Lord,
S. (2014). Metastatic breast cancer in young
women: a population-based cohort study to
Publications for Chee Khoon Lee
describe risk and prognosis. Internal Medicine
Journal, 44(8), 764-770. <a
href="http://dx.doi.org/10.1111/imj.12481">[Mo
re Information]</a>
Stockler, M., Hilpert, F., Friedlander, M., King,
M., Wenzel, L., Lee, C., Joly, F., de Gregorio,
N., Arranz, J., Mirza, M., et al (2014).
Patient-Reported Outcome Results From the
Open-Label Phase III AURELIA Trial
Evaluating Bevacizumab-Containing Therapy for
Platinum-Resistant Ovarian Cancer. Journal of
Clinical Oncology, 32(13), 1309-1319. <a
href="http://dx.doi.org/10.1200/JCO.2013.51.42
40">[More Information]</a>
Bruhn, M., Townsend, A., Lee, C., Shivasami,
A., Price, T., Wrin, J., Arentz, G., Tebbutt, N.,
Hocking, C., Cunningham, D., et al (2014).
Proangiogenic tumor proteins as potential
predictive or prognostic biomarkers for
bevacizumab therapy in metastatic colorectal
cancer. International Journal of Cancer, 135(3),
731-741. <a
href="http://dx.doi.org/10.1002/ijc.28698">[Mor
e Information]</a>
2013
Lee, C., Simes, R., Brown, C., Gebski, V.,
Pfisterer, J., Swart, A., Berton-Rigaud, D.,
Plante, M., Skeie-Jensen, T., Vergote, I., Lord,
S., et al (2013). A prognostic nomogram to
predict overall survival in patients with
platinum-sensitive recurrent ovarian cancer.
Annals of Oncology, 24(4), 937-943. <a
href="http://dx.doi.org/10.1093/annonc/mds538"
>[More Information]</a>
Lee, C., Brown, C., Gralla, R., Hirsh, V.,
Thongprasert, S., Tsai, C., Tan, E., Ho, J., Chu,
D., Zaatar, A., Gebski, V., et al (2013). Impact of
EGFR Inhibitor in Non-Small Cell Lung Cancer
on Progression-Free and Overall Survival: A
Meta-Analysis. Journal of the National Cancer
Institute, 105(9), 595-605. <a
href="http://dx.doi.org/10.1093/jnci/djt072">[M
ore Information]</a>
href="http://dx.doi.org/10.1002/cam4.75">[More
Information]</a>
You, B., Colomban, O., Heywood, M., Lee, C.,
Davy, M., Reed, N., Pignata, S., Varsellona, N.,
Emons, G., Rehman, K., et al (2013). The strong
prognostic value of KELIM, a model-based
parameter from CA 125 kinetics in ovarian
cancer: data from CALYPSO trial (a
GINECO-GCIG study). Gynecologic Oncology,
130(2), 289-294. <a
href="http://dx.doi.org/10.1016/j.ygyno.2013.05.
013">[More Information]</a>
Lee, C., Gebski, V., Coates, A., Veillard, A.,
Harvey, V., Tattersall, M., Byrne, M., Brigham,
B., Forbes, J., Simes, R. (2013). Trade-offs in
quality of life and survival with chemotherapy
for advanced breast cancer: mature results of a
randomized trial comparing single-agent
mitoxantrone with combination
cyclophosphamide, methotrexate, 5-fluorouracil
and prednisone. SpringerPlus, 2(391), 1-10. <a
href="http://dx.doi.org/10.1186/2193-1801-2-39
1">[More Information]</a>
2012
Carter, H., Lord, S., Martin, A., Gill, G., Lee, C.,
Howard, K., Wetzig, N., Simes, R. (2012).
Effectiveness and cost-effectiveness of sentinel
lymph node biopsy compared with axillary node
dissection in patients with early-stage breast
cancer: a decision model analysis. British
Journal of Cancer, 106(6), 1045-1052. <a
href="http://dx.doi.org/10.1038/bjc.2012.62">[M
ore Information]</a>
Lee, C., Marschner, I., Simes, R., Voysey, M.,
Egleston, B., Hudes, G., de Souza, P. (2012).
Increase in Cholesterol PredictsSsurvival
Advantage in Renal Cell Carcinoma Patients
Treated with Temsirolimus. Clinical Cancer
Research, 18(11), 3188-3196. <a
href="http://dx.doi.org/10.1158/1078-0432.CCR11-3137">[More Information]</a>
2011
Fox, P., Hudson, M., Brown, C., Lord, S.,
Gebski, V., de Souza, P., Lee, C. (2013).
Markers of systemic inflammation predict
survival in patients with advanced renal cell
cancer. British Journal of Cancer, 109(1),
147-153. <a
href="http://dx.doi.org/10.1038/bjc.2013.300">[
More Information]</a>
Lee, C., Hudson, M., Stockler, M., Coates, A.,
Ackland, S., Gebski, V., Lord, S., Friedlander,
M., Boyle, F., Simes, R. (2011). A nomogram to
predict survival time in women starting first-line
chemotherapy for advanced breast cancer. Breast
Cancer Research and Treatment, 129(2),
467-476. <a
href="http://dx.doi.org/10.1007/s10549-011-147
1-9">[More Information]</a>
Price, T., Hardingham, J., Lee, C., Townsend,
A., Wrin, J., Wilson, K., Weickhardt, A., Simes,
R., Murone, C., Tebbutt, N. (2013). Prognostic
impact and the relevance of PTEN copy number
alterations in patients with advanced colorectal
cancer (CRC) receiving bevacizumab. Cancer
Medicine, 2(3), 277-285. <a
Lee, C., Gurney, H., Brown, C., Sorio, R.,
Donadello, N., Tulunay, G., Meier, W., Bacon,
M., Maenpaa, J., Petru, E., Gebski, V., Lord, S.,
Simes, R., et al (2011).
Carboplatin-paclitaxel-induced leukopenia and
neuropathy predict progression-free survival in
Publications for Chee Khoon Lee
recurrent ovarian cancer. British Journal of
Cancer, 105(3), 360-365. <a
href="http://dx.doi.org/10.1038/bjc.2011.256">[
More Information]</a>
Lee, C., Friedlander, M., Brown, C., Gebski, V.,
Georgoulopoulos, A., Vergote, I., Pignata, S.,
Donadello, N., Schmalfeldt, B., Delva, R., Lord,
S., Simes, R., et al (2011). Early Decline in
Cancer Antigen 125 as a Surrogate for
Progression-Free Survival in Recurrent Ovarian
Cancer. Journal of the National Cancer Institute,
103(17), 1338-1342. <a
href="http://dx.doi.org/10.1093/jnci/djr282">[M
ore Information]</a>
Price, T., Hardingham, J., Lee, C., Townsend,
A., Wrin, J., Chua, A., Shivasami, A., Parry, M.,
Weikhardt, A., Tebbutt, N., et al (2011). Impact
of KRAS and BRAF Gene Mutation Status on
Outcomes From the Phase III AGITG MAX
Trial of Capecitabine Alone or in Combination
With Bevacizumab and Mitomycin in Advanced
Colorectal Cancer. Journal of Clinical Oncology,
29(19), 2675-2682. <a
href="http://dx.doi.org/10.1200/JCO.2010.34.55
20">[More Information]</a>
Lee, C., Simes, R., Brown, C., Lord, S., Wagner,
U., Plante, M., Vergote, I., Pisano, C., Parma, G.,
Burges, A., Gebski, V., et al (2011). Prognostic
nomogram to predict progression-free survival in
patients with platinum-sensitive recurrent
ovarian cancer. British Journal of Cancer,
105(8), 1144-1150. <a
href="http://dx.doi.org/10.1038/bjc.2011.364">[
More Information]</a>
2010
Lee, C., Lord, S., Stockler, M., Coates, A.,
Gebski, V., Simes, R. (2010). Historical
cross-trial comparisons for competing treatments
in advanced breast cancer - An empirical
analysis of bias. European Journal of Cancer,
46(3), 541-548. <a
href="http://dx.doi.org/10.1016/j.ejca.2009.11.01
3">[More Information]</a>
Kiely, B., Lee, C., Tattersall, M., Stockler, M.
(2010). How long have I got? Estimating
post-progression survival after first line
chemotherapy for metastatic breast cancer based
on data from randomized trials. 33rd Annual
CTRC-AACR San Antonio Breast Cancer
Symposium.
Lee, C., Stockler, M., Coates, A., Gebski, V.,
Lord, S., Simes, R. (2010). Self-reported
health-related quality of life is an independent
predictor of chemotherapy treatment benefit and
toxicity in women with advanced breast cancer.
British Journal of Cancer, 102(9), 1341-1347. <a
href="http://dx.doi.org/10.1038/sj.bjc.6605649">
[More Information]</a>
2009
Lee, C., Lord, S., Coates, A., Simes, R. (2009).
Molecular biomarkers to individualise treatment:
assessing the evidence. Medical Journal of
Australia, 190(11), 631-636. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=19485842">[More Information]</a>
Chua, W., Goldstein, D., Lee, C., Dhillon, H.,
Michael, M., Mitchell, P., Clark, S., Iacopetta, B.
(2009). Molecular markers of response and
toxicity to FOLFOX chemotherapy in metastatic
colorectal cancer. British Journal of Cancer,
101(6), 998-1004. <a
href="http://dx.doi.org/10.1038/sj.bjc.6605239">
[More Information]</a>
Lee, C., Hadley, A., DeSilva, K., Smith, G.,
Goldstein, D. (2009). When is a GIST not a
GIST? A case report of synchronous metastatic
gastrointestinal stromal tumor and fibromatosis.
World Journal of Surgical Oncology, 7(8), 1-4.
<a
href="http://dx.doi.org/10.1186/1477-7819-7-8"
>[More Information]</a>
2008
Lord, S., Lee, C., Simes, R. (2008). The Role of
Predictive and Prognostic Markers in Cancer.
Cancer Forum, 32(3), 139-142.